OBJECTIVE: To measure the impact of botulinum toxin A on associated reactions in patients following stroke. DESIGN: Randomized placebo-controlled trial. PATIENTS: Forty patients with spasticity in their paretic arm (median time since stroke: 2.7 years) were randomized to botulinum toxin A (Dysport; 1000 mouse units (MU) divided between elbow, wrist and finger flexors) or placebo. METHODS: Associated reactions were measured using hand dynamometry. The effort used was measured using maximum voluntary grip in the unaffected arm. Measurements were recorded at 2 pre-treatment and 3 post-intervention times. Activities that patients felt caused associated reactions and activities that were affected by associated reactions were recorded. RESULTS:Peak associated reactions force was reduced at week 6 with botulinum toxin A compared with placebo (mean group difference 19.0 N; 95% confidence interval (CI): 7.2, 30.9; p < 0.01) and week 2 (p = 0.005), with the effect wearing off by week 12 (p = 0.09). Thirty-one patients noted associated reactions on a regular basis and 24 said that these movements interfered with daily activities. Ten of 12 patients receivingbotulinum toxin A and 2 of 12 receiving placebo reported reduction in interference with daily activities (p = 0.02). CONCLUSION:Botulinum toxin A reduces associated reactions and may be a useful adjunct to other rehabilitation interventions. The impact of associated reactions on daily activities may also be reduced.
RCT Entities:
OBJECTIVE: To measure the impact of botulinum toxin A on associated reactions in patients following stroke. DESIGN: Randomized placebo-controlled trial. PATIENTS: Forty patients with spasticity in their paretic arm (median time since stroke: 2.7 years) were randomized to botulinum toxin A (Dysport; 1000 mouse units (MU) divided between elbow, wrist and finger flexors) or placebo. METHODS: Associated reactions were measured using hand dynamometry. The effort used was measured using maximum voluntary grip in the unaffected arm. Measurements were recorded at 2 pre-treatment and 3 post-intervention times. Activities that patients felt caused associated reactions and activities that were affected by associated reactions were recorded. RESULTS: Peak associated reactions force was reduced at week 6 with botulinum toxin A compared with placebo (mean group difference 19.0 N; 95% confidence interval (CI): 7.2, 30.9; p < 0.01) and week 2 (p = 0.005), with the effect wearing off by week 12 (p = 0.09). Thirty-one patients noted associated reactions on a regular basis and 24 said that these movements interfered with daily activities. Ten of 12 patients receiving botulinum toxin A and 2 of 12 receiving placebo reported reduction in interference with daily activities (p = 0.02). CONCLUSION: Botulinum toxin A reduces associated reactions and may be a useful adjunct to other rehabilitation interventions. The impact of associated reactions on daily activities may also be reduced.
Authors: J Wissel; M auf dem Brinke; M Hecht; C Herrmann; M Huber; S Mehnert; I Reuter; A Schramm; A Stenner; C van der Ven; M Winterholler; A Kupsch Journal: Nervenarzt Date: 2011-04 Impact factor: 1.214
Authors: Shannon Pike; Anne Cusick; Kylie Wales; Lisa Cameron; Lynne Turner-Stokes; Stephen Ashford; Natasha A Lannin Journal: PLoS One Date: 2021-02-11 Impact factor: 3.240
Authors: Carlo Trompetto; Lucio Marinelli; Laura Mori; Elisa Pelosin; Antonio Currà; Luigi Molfetta; Giovanni Abbruzzese Journal: Biomed Res Int Date: 2014-10-30 Impact factor: 3.411
Authors: Michelle B Kahn; Ross A Clark; Gavin Williams; Kelly J Bower; Megan Banky; John Olver; Benjamin F Mentiplay Journal: J Neuroeng Rehabil Date: 2019-12-27 Impact factor: 4.262